Adverum Biotechnologies to Present New Data from the OPTIC Phase 1 Trial of ADVM-022 Intravitreal Gene Therapy for Wet AMD at...
October 20 2020 - 9:00AM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene
therapy company targeting unmet medical needs in ocular and rare
diseases, today announced the presentation of additional clinical
data for Cohorts 1-4 in the OPTIC Phase 1 clinical trial of
ADVM-022 intravitreal injection gene therapy in wet age-related
macular degeneration (wet AMD). This will be in the form of a live
broadcast during the American Academy of Ophthalmology (AAO) 2020
Virtual Meeting.
Presentation of New OPTIC
Data:Event: Retina Subspecialty Day 2020
Virtual MeetingTitle: Intravitreal Gene Therapy with ADVM-022 for
Neovascular AMD: OPTIC Phase 1 StudyDate: November 13, 2020Time:
2:15 pm PTPresenter: Carl Regillo, M.D., F.A.C.S, chief of retina
services at Wills Eye HospitalPresentation: At the beginning of Dr.
Regillo’s presentation, Adverum plans to issue a press release and
post the new data presentation under Events and Presentations in
the Investors section of the company’s website.
Presentation of
Existing OPTIC
Data:Event: AAO 2020 Virtual
MeetingTitle: Phase 1 Study of Intravitreal Gene Therapy with
ADVM-022 for Neovascular AMD (OPTIC Trial Cohorts 1-4, from the
August 10, 2020 data presentation)Date: November 14-17,
2020Presenter: Arshad M. Khanani, M.D., M.A., managing partner and
director of clinical research, Sierra Eye Associates, clinical
associate professor of ophthalmology, University of
NevadaPresentation: On or before November 13, 2020 the virtual
presentations will be available on demand to AAO participants, and
Adverum plans to post the presentation under Events and
Presentations in the Investors section of the company’s
website.
Adverum
Webcast:Date: November 14,
2020Time: 7:30 – 9:00 am PT (10:30 am – 12:00 pm ET)Presenters:
- Carl Regillo, M.D., F.A.C.S, chief of retina services at Wills
Eye Hospital and investigator in the OPTIC Phase 1 trial
- Steven Yeh, M.D., associate professor, director, section of
uveitis and ocular immunology, Emory Eye Center
- David S. Boyer, M.D., senior partner, Retina-Vitreous
Associates Medical Group and adjunct clinical professor of
ophthalmology, University of Southern California/ Keck School of
Medicine, Los Angeles, investigator in the OPTIC Phase 1 trial
The live video webcast will be accessible under
Events and Presentations in the Investors section of the company's
website. The archived audio webcast will be available on the
Adverum website following the call and will be available for 30
days.
On November 5, 2020 after market, Adverum plans to
report recent business progress and financial results for the third
quarter of 2020. The Company plans to host the KOL webcast on
November 14, 2020 to review new OPTIC data instead of hosting a
quarterly conference call this quarter.
About Adverum
BiotechnologiesAdverum Biotechnologies (Nasdaq: ADVM) is a
clinical-stage gene therapy company targeting unmet medical needs
in serious ocular and rare diseases. Adverum is advancing the
clinical development of its novel gene therapy candidate, ADVM-022,
as a one-time, intravitreal injection for the treatment of patients
with wet age-related macular degeneration and diabetic macular
edema. For more information, please visit www.adverum.com.
Investor and Media Inquiries:
Myesha Lacy
Vice President, Investor Relations and Corporate Communications
Adverum Biotechnologies, Inc.
mlacy@adverum.com
1-650-649-1257
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Apr 2023 to Apr 2024